-
1 Comment
Bone Therapeutics SA is currently in a long term downtrend where the price is trading 2.6% below its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.1.
Based on the above factors, Bone Therapeutics SA gets an overall score of 1/5.
| ISIN | BE0974280126 |
|---|---|
| Exchange | F |
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 1M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | -2.29 |
| Dividend Yield | None |
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BT1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026